Alexion moves to buy biotech for up to $1.2bn

01-10-2018

Alexion moves to buy biotech for up to $1.2bn

Xesai / iStockphoto.com

US-based Alexion Pharmaceuticals has announced its plan to acquire Syntimmune, a clinical-stage biotechnology company. 


Alexion Pharmaceuticals, Syntimmune, biotech, mergers and acquisitions, M&A, antibody therapeutics, 


LSIPR